If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Started

MRNA has surged 650% in 2026, and the move traces to one catalyst: intismeran, its cancer vaccine developed with MRK. In recent trials, intismeran combined with MRK's Keytruda cut the risk of melanoma death or recurrence by 42%.

That figure is the foundation of the rally. CEO Stéphane Bancel argues the opportunity extends well beyond melanoma. He believes intismeran could work across multiple cancer types where Keytruda is already effective. If he's right, the addressable market for the vaccine expands with every additional indication Keytruda treats. That is the bull case, and it is Bancel's claim, not a demonstrated result.

The risks are concrete. Intismeran remains unapproved, so the 650% gain prices in a regulatory outcome that hasn't happened. After a move that size, the stock carries sky-high expectations, leaving little room for disappointment. Interpretation: when a single asset drives nearly all of a stock's repricing, any trial setback, delay, or narrower-than-hoped label could hit shares harder than good news lifts them.

MRK sits on the other side of the trade. As Keytruda's maker and intismeran's partner, it shares in the program, though the source ties the 650% surge to MRNA alone.